Literature DB >> 16100046

Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.

Mohamad Navab1, G M Anantharamaiah, Srinivasa T Reddy, Susan Hama, Greg Hough, Joy S Frank, Victor R Grijalva, Vannakambadi K Ganesh, Vinod K Mishra, Mayakonda N Palgunachari, Alan M Fogelman.   

Abstract

A peptide containing only 4 amino acid residues (KRES) that is too small to form an amphipathic helix, reduced lipoprotein lipid hydroperoxides (LOOH), increased paraoxonase activity, increased plasma HDL-cholesterol levels, rendered HDL antiinflammatory, and reduced atherosclerosis in apoE null mice. KRES was orally effective when synthesized from either L or D-amino acids suggesting that peptide-protein interactions were not required. Remarkably, changing the order of 2 amino acids (from KRES to KERS) resulted in the loss of all biologic activity. Solubility in ethyl acetate and interaction with lipids, as determined by differential scanning calorimetry, indicated significant differences between KRES and KERS. Negative stain electron microscopy showed that KRES formed organized peptide-lipid structures whereas KERS did not. Another tetrapeptide FREL shared many of the physical-chemical properties of KRES and was biologically active in mice and monkeys when synthesized from either L- or D-amino acids. After oral administration KRES and FREL were found associated with HDL whereas KERS was not. We conclude that the ability of peptides to interact with lipids, remove LOOH and activate antioxidant enzymes associated with HDL determines their antiinflammatory and antiatherogenic properties regardless of their ability to form amphipathic helixes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100046     DOI: 10.1161/01.RES.0000181229.69508.2f

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  22 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

2.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

3.  Peptide Mimetics of Apolipoproteins Improve HDL Function.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Alan M Fogelman
Journal:  J Clin Lipidol       Date:  2007-05       Impact factor: 4.766

Review 4.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

Review 5.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

6.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

Review 7.  Structure and function of HDL mimetics.

Authors:  Mohamad Navab; Ishaiahu Shechter; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-16       Impact factor: 8.311

8.  Oxpholipin 11D: an anti-inflammatory peptide that binds cholesterol and oxidized phospholipids.

Authors:  Piotr Ruchala; Mohamad Navab; Chun-Ling Jung; Susan Hama-Levy; Ewa D Micewicz; Hai Luong; Jonathan E Reyles; Shantanu Sharma; Alan J Waring; Alan M Fogelman; Robert I Lehrer
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

9.  Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Authors:  Salil Sharma; Soban Umar; Francois Potus; Andrea Iorga; Gabriel Wong; David Meriwether; Sandra Breuils-Bonnet; Denise Mai; Kaveh Navab; David Ross; Mohamad Navab; Steeve Provencher; Alan M Fogelman; Sébastien Bonnet; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Circulation       Date:  2014-06-24       Impact factor: 29.690

10.  Atherosclerosis regression.

Authors:  Justin M S Lee; Alistair C Lindsay; Ilias Kylintireas; Robin P Choudhury
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.